Erratum: Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis (Hepatology (2016) 63 (898-913) DOI: 10.1002/hep.28372);Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis

Hepatology

Volumn 63, Issue 3, 2016, Pages 898-913

  Guo, Hui ^a,b   Jing, Li ^a   Cheng, Yangzi ^a   Atsaves, Vassilis ^c   Lv, Yi ^a,d   Wu, Tao ^a   Su, Rujuan ^a   Zhang, Yamin ^a   Zhang, Ronghua ^b   Liu, Wenbin ^e   Rassidakis, George Z ^f   Wei, Yongchang ^a   Nan, Kejun ^a   Claret, Francois X ^b,g  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF ATHENS   (Greece)

^d THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^e UNIVERSITY OF TEXAS   (United States)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1C; JAB 1 PROTEIN; PROTEIN KINASE B; S PHASE KINASE ASSOCIATED PROTEIN 2; UNCLASSIFIED DRUG; ATP DEPENDENT 26S PROTEASE; CDKN1C PROTEIN, HUMAN; COPS5 PROTEIN, HUMAN; PEPTIDE HYDROLASE; PROTEASOME; S PHASE KINASE ASSOCIATED PROTEIN; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL THERAPY; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; ANIMAL; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; FEMALE; LIVER NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P57; DOWN-REGULATION; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE HYDROLASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-AKT; RATS, SPRAGUE-DAWLEY; S-PHASE KINASE-ASSOCIATED PROTEINS;

EID: 84954289081     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1097/HEP.0000000000000451     Document Type: Erratum

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-1491.
3. Lee JO, Lee KW, Oh DY, Kim JH, Im SA, Kim TY, et al. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol 2009;20:1402-1407.
4. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, et al. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995;9:650-662.
5. Zhang P, Liégeois NJ, Wong C, Finegold M, Hou H, Thompson JC, et al. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 1997;387:151-158.
6. Matsumoto A, Takeishi S, Nakayama KI. p57 regulates T-cell development and prevents lymphomagenesis by balancing p53 activity and pre-TCR signaling. Blood 2014;123:3429-3439.
7. Kavanagh E, Vlachos P, Emourgeon V, Rodhe J, Joseph B. p57(KIP2) control of actin cytoskeleton dynamics is responsible for its mitochondrial pro-apoptotic effect. Cell Death Dis 2012;3:e311.
8. Vlachos P, Joseph B. The Cdk inhibitor p57(Kip2) controls LIM-kinase 1 activity and regulates actin cytoskeleton dynamics. Oncogene 2009;28:4175-4188.
9. Borriello A, Caldarelli I, Bencivenga D, Criscuolo M, Cucciolla V, Tramontano A, et al. p57(Kip2) and cancer: time for a critical appraisal. Mol Cancer Res 2011;9:1269-1284.
10. Larson PS, Schlechter BL, King CL, Yang Q, Glass CN, Mack C, et al. CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer. BMC Cancer 2008;8:68.
11. Jin RJ, Lho Y, Wang Y, Ao M, Revelo MP, Hayward SW, et al. Down-regulation of p57Kip2 induces prostate cancer in the mouse. Cancer Res 2008;68:3601-3608.
12. Agarwal A, Mackenzie RJ, Besson A, Jeng S, Carey A, LaTocha DH, et al. Deininger MW8. BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. Blood 2014;124:3260-3273.
13. Guo H, Lv Y, Tian T, Hu TH, Wang WJ, Sui X, et al. Downregulation of p57 accelerates the growth and invasion of hepatocellular carcinoma. Carcinogenesis 2011;32:1897-1904.
14. Yuan Q, Loya K, Rani B, Möbus S, Balakrishnan A, Lamle J, et al. MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology 2013;57:299-310.
15. Delogu S, Wang C, Cigliano A, Utpatel K, Sini M, Longerich T, et al. SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice. Oncotarget 2015;6:2222-2234.
16. Lee MP, DeBaun M, Randhawa G, Reichard BA, Elledge SJ, Feinberg AP. Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome. Am J Hum Genet 1997;61:304-309.
17. Figliola R, Busanello A, Vaccarello G, Maione R. Regulation of p57(KIP2) during muscle differentiation: role of Egr1, Sp1 and DNA hypomethylation. J Mol Biol 2008;380:265-277.
18. Nishimori S, Tanaka Y, Chiba T, Fujii M, Imamura T, Miyazono K, et al. Smad-mediated transcription is required for transforming growth factor-beta 1-induced p57(Kip2) proteolysis in osteoblastic cells. J Biol Chem 2001;276:10700-10705.
19. Giovannini C, Gramantieri L, Minguzzi M, Fornari F, Chieco P, Grazi GL, et al. CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma. Am J Pathol 2012;181:413-422.
20. Kamura T, Hara T, Kotoshiba S, Yada M, Ishida N, Imaki H, et al. Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Nat Acad Sci U S A 2003;100:10231-10236.
21. Zhao R, Yang HY, Shin J, Phan L, Fang L, Che TF, et al. CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity. Cell Cycle 2013;12:935-943.
22. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, et al. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res 2014;20:2226-2235.
23. Claret FX, Hibi M, Dhut S, Toda T, Karin M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature 1996;383:453-457.
24. Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 1999;398:160-165.
25. Hsu MC, Huang CC, Chang HC, Hu TH, Hung WC. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor ligands in vitro and in vivo. Clin Cancer Res 2008;14:4045-4052.
26. Lee YH, Judge AD, Seo D, Kitade M, Gómez-Quiroz LE, Ishikawa T, et al. Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response. Oncogene 2011;30:4175-4184.
27. Pan Y, Zhang Q, Tian L, Wang X, Fan X, Zhang H, et al. Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma. Cancer Res 2012;72:1890-1900.
28. Kouvaraki MA, Korapati AL, Rassidakis GZ, Tian L, Zhang Q, Chiao P, et al. Potential role of Jun activation domain-binding protein 1 as a negative regulator of p27kip1 in pancreatic adenocarcinoma. Cancer Res 2006;66:8581-8589.
29. Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C, Claret FX. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Res 2003;63:2977-2981.
30. Zou P, Yoshihara H, Hosokawa K, Tai I, Shinmyozu K, Tsukahara F, et al. p57(Kip2) and p27(Kip1) cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70. Cell Stem Cell 2011;9:247-261.
31. Jacobsen Skanderup A. cgdsr: R-based API for accessing the MSKCC Cancer Genomics Data Server. R package version 1.1.33.
32. Prieto J. Inflammation, HCC and sex: IL-6 in the centre of the triangle. J Hepatol 2008;48:380-381.
33. Lee SW, Li CF, Jin G, Cai Z, Han F, Chan CH, et al. Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell survival under energy stress. Mol Cell 2015;57:1022-1033.
34. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-1101.
35. Pan Y, Zhang Q, Atsaves V, Yang H, Claret FX. Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways. Oncogene 2013;32:2756-2766.
36. Calvisi DF, Ladu S, Pinna F, Frau M, Tomasi ML, Sini M, et al. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology 2009;137:1816-1826.
37. Cai JB, Shi GM, Dong ZR, Ke AW, Ma HH, Gao Q, et al. Ubiquitin-specific protease 7 accelerates p14(ARF) degradation by deubiquitinating thyroid hormone receptor-interacting protein 12 and promotes hepatocellular carcinoma progression. Hepatology 2015;61:1603-1614.
38. Wei N, Serino G, Deng XW. The COP9 signalosome: more than a protease. Trends Biochem Sci 2008;33:592-600.
39. Kim M, Nakamoto T, Nishimori S, Tanaka K, Chiba T. A new ubiquitin ligase involved in p57KIP2 proteolysis regulates osteoblast cell differentiation. EMBO Rep 2008;9:878-884.
40. Chen B, Zhao R, Su CH, Linan M, Tseng C, Phan L, et al. CDK inhibitor p57 (Kip2) is negatively regulated by COP9 signalosome subunit 6. Cell Cycle 2012;11:4633-4641.
41. Osoegawa A, Yoshino I, Kometani T, Yamaguchi M, Kameyama T, Yohena T, et al. Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features. Cancer 2006;107:154-161.
42. Wang Y, Yu YN, Song S, Li TJ, Xiang JY, Zhang H, et al. JAB1 and phospho-Ser10 p27 expression profile determine human hepatocellular carcinoma prognosis. J Cancer Res Clin Oncol 2014;140:969-978.
43. Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, et al. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene 2010;29:6125-6137.